Faculty

Donald P. Levine, MD, FACP

Default Biography Avatar
Professor of Medicine, Wayne State University, Detroit, MI

Donald P. Levine, M.D. is Professor of Medicine at Wayne State University in Detroit, Michigan. He is Board Certified in Internal Medicine and Infectious Diseases and is Associate Vice Chair for Continuing Medical Education and Community Affairs for the Department of Internal Medicine at Wayne State University and former Chief of Staff at Detroit Receiving Hospital. He attended the University of Michigan, the University of Illinois School of Law and is a graduate of Wayne State University’s medical school. He served as an intern and resident in internal medicine at the Hutzel Hospital Medical Unit of Wayne State University. He served as an Infectious Disease fellow at Wayne State and completed his fellowship as a special fellow of the National Institute of Neurological Diseases and Stroke. He joined the faculty of Wayne State University in 1978, first at Detroit General Hospital and subsequently, when the hospital moved and was renamed, at Detroit Receiving Hospital. Dr. Levine has long had an interest in infective endocarditis and staphylococcal infections. He reported the first appearance of community acquired methicillin-resistant Staphylococcus aureus among injection drug users and described methicillin-resistant S. aureus endocarditis. He also reported the slow response to vancomycin associated with its use in patients with endocarditis. With Dr. Jack Sobel, Dr. Levine edited the book, “Infections in Intravenous Drug Users”. He has also written numerous articles, book chapters and editorials. He was a member of the panel that produced the consensus guidelines for vancomycin use and is also a member of the Infectious Disease Society of America’s panel that produced the consensus guidelines for the management of MRSA infections. In an effort to help develop new approaches to the problem of increasing antibiotic resistance among staphylococci he has participated in a number of studies comparing investigational antibiotics to standard therapy for patients with methicillin-resistant S. aureus infective endocarditis and is currently the principle investigator of several ongoing studies designed to evaluate novel approaches to the management of staphylococcal infections.